11月10日 - HHS:FDA还批准了两种新药,以拓展更年期症状的治疗选择;FDA并不寻求取消针对单纯系统雌激素产品的子宫内膜癌的盒装警告;FDA为了扩大更年期症状的治疗选项,正在批准一种Premarin(结合雌激素)的仿制药。
11月10日 - HHS:FDA还批准了两种新药,以拓展更年期症状的治疗选择;FDA并不寻求取消针对单纯系统雌激素产品的子宫内膜癌的盒装警告;FDA为了扩大更年期症状的治疗选项,正在批准一种Premarin(结合雌激素)的仿制药。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.